Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367446 | 0.91 | CXCR2 (0.34) | TSHRCXCR2 | |
| SCHEMBL3367792 | 0.87 | TSHR (0.43) | TSHRCXCR2ALDH1A1POLBTP53 | |
| SCHEMBL3368029 | 0.86 | TP53 (0.34) | CXCR2TP53 | |
| SCHEMBL3368603 | 0.84 | ALDH1A1 (0.45) | TSHRCXCR2ALDH1A1POLBTP53 | |
| SCHEMBL3368708 | 0.83 | TSHR (0.44) | TSHRCXCR2ALDH1A1POLBTP53 | |
| SCHEMBL3344931 | 0.82 | CXCR2 (0.34) | CXCR2ALDH1A1 | |
| SCHEMBL3365721 | 0.82 | NPC1 (0.34) | POLBTP53SMN1; SMN2MAPT | |
| SCHEMBL3367417 | 0.82 | L3MBTL1 (0.34) | ALDH1A1TP53SMN1; SMN2MAPT | |
| SCHEMBL3365523 | 0.80 | ALDH1A1 (0.43) | TSHRALDH1A1POLBTP53MAPT | |
| SCHEMBL3368020 | 0.80 | TSHR (0.46) | TSHRCXCR2ALDH1A1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | claimed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | claimed |
| EP-2094696-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008061741-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | disclosed |
| EP-2094696-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061741-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069407-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | TSHR 2129/4885CXCR2 1/4885ALDH1A1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.